You are here

Safety and Tolerability of Once-Daily OROS(®) Hydromorphone Extended-Release in Opioid-Tolerant Adults With Moderate-to-Severe Chronic Cancer and Noncancer Pain: Pooled Analysis of 11 Clinical Studies.